यूनाइटेड किंगडम - अंग्रेज़ी - MHRA (Medicines & Healthcare Products Regulatory Agency)

imported (korea) - japanese encephalitis virus - solution for injection

यूनाइटेड किंगडम - अंग्रेज़ी - MHRA (Medicines & Healthcare Products Regulatory Agency)

imported (korea) - japanese encephalitis virus - solution for injection

इसराइल - अंग्रेज़ी - Ministry of Health

kamada ltd, israel - japanese encephalitis purified inactivated vaccine - suspension for injection - japanese encephalitis purified inactivated vaccine 6 au / 0.5 ml - encephalitis, japanese, inactivated, whole virus - ixiaro is indicated for active immunization against japanese encephalitis in adults, adolescents, children and infants aged 2 months and older. ixiaro should be considered for use in individuals at risk of exposure through travel or in the course of their occupation.

ऑस्ट्रेलिया - अंग्रेज़ी - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme (australia) pty ltd - hepatitis a virus, quantity: 50 u/ml - injection - excipient ingredients: aluminium; water for injections; borax; sodium chloride - vaqta is indicated for active pre-exposure prophylaxis against disease caused by hepatitis a virus in persons 12 months of age and older. primary immunisation should be given at least 2 weeks prior to expected exposure to hepatitis a virus. individuals who are or will be increased risk of infection include: travellers to areas of intermediate or high endemicity for hepatitis a. persons for whom hepatitis a is an occupational hazard. employee of child day-care centers. certain institutional workers (eg. caretakers for the intellectually disabled). health workers and teachers in remote aboriginal and torres strait islander communities. nursing staff and other health care workers in contact with patients in paediatric wards and infectious disease wards. sewerage workers. recipients of blood products. individuals with chronic liver disease and those who have had a liver transplant. homosexually active males. human immunodeficiency virus (hiv)-infected adults.

ऑस्ट्रेलिया - अंग्रेज़ी - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme (australia) pty ltd - hepatitis a virus, quantity: 50 u/ml - injection - excipient ingredients: borax; aluminium; sodium chloride; water for injections - vaqta is indicated for active pre-exposure prophylaxis against disease caused by hepatitis a virus in persons 12 months of age and older. primary immunisation should be given at least 2 weeks prior to expected exposure to hepatitis a virus. individuals who are or will be increased risk of infection include: travellers to areas of intermediate or high endemicity for hepatitis a. persons for whom hepatitis a is an occupational hazard. employee of child day-care centers. certain institutional workers (eg. caretakers for the intellectually disabled). health workers and teachers in remote aboriginal and torres strait islander communities. nursing staff and other health care workers in contact with patients in paediatric wards and infectious disease wards. sewerage workers. recipients of blood products. individuals with chronic liver disease and those who have had a liver transplant. homosexually active males. human immunodeficiency virus (hiv)-infected adults.

ऑस्ट्रेलिया - अंग्रेज़ी - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme (australia) pty ltd - hepatitis a virus, quantity: 50 u/ml - injection - excipient ingredients: borax; water for injections; sodium chloride; aluminium - vaqta is indicated for active pre-exposure prophylaxis against disease caused by hepatitis a virus in persons 12 months of age and older. primary immunisation should be given at least 2 weeks prior to expected exposure to hepatitis a virus. individuals who are or will be increased risk of infection include: travellers to areas of intermediate or high endemicity for hepatitis a. persons for whom hepatitis a is an occupational hazard. employee of child day-care centers. certain institutional workers (eg. caretakers for the intellectually disabled). health workers and teachers in remote aboriginal and torres strait islander communities. nursing staff and other health care workers in contact with patients in paediatric wards and infectious disease wards. sewerage workers. recipients of blood products. individuals with chronic liver disease and those who have had a liver transplant. homosexually active males. human immunodeficiency virus (hiv)-infected adults.

ऑस्ट्रेलिया - अंग्रेज़ी - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme (australia) pty ltd - hepatitis a virus, quantity: 50 u/ml - injection - excipient ingredients: sodium chloride; borax; water for injections; aluminium - vaqta is indicated for active pre-exposure prophylaxis against disease caused by hepatitis a virus in persons 12 months of age and older. primary immunisation should be given at least 2 weeks prior to expected exposure to hepatitis a virus. individuals who are or will be increased risk of infection include: travellers to areas of intermediate or high endemicity for hepatitis a. persons for whom hepatitis a is an occupational hazard. employee of child day-care centers. certain institutional workers (eg. caretakers for the intellectually disabled). health workers and teachers in remote aboriginal and torres strait islander communities. nursing staff and other health care workers in contact with patients in paediatric wards and infectious disease wards. sewerage workers. recipients of blood products. individuals with chronic liver disease and those who have had a liver transplant. homosexually active males. human immunodeficiency virus (hiv)-infected adults.

संयुक्त राज्य - अंग्रेज़ी - NLM (National Library of Medicine)

sanofi pasteur inc. - yellow fever virus strain 17d-204 live antigen (unii: py4eet359t) (yellow fever virus strain 17d-204 live antigen - unii:py4eet359t) - yellow fever virus strain 17d-204 live antigen 1000 [iu] in 0.5 ml

संयुक्त राज्य - अंग्रेज़ी - NLM (National Library of Medicine)

the wellness center for research and education, inc. - horseradish (unii: 8ds6g120hj) (horseradish - unii:8ds6g120hj), human herpesvirus 3 (unii: 9885m7d6jp) (human herpesvirus 3 - unii:9885m7d6jp), sus scrofa spleen (unii: 92amn5j79y) (sus scrofa spleen - unii:92amn5j79y), sus scrofa thymus (unii: 7b69b0bd62) (sus scrofa thymus - unii:7b69b0bd62), pork liver (unii: 6ec706hi7f) (pork liver - unii:6ec706hi7f), human herpesvirus 4 (unii: 2a26yw7pnx) (human herpesvirus 4 - unii:2a26yw7pnx), measles virus (unii: ht3r7c012q) (measles virus - unii:ht3r7c012q), - horseradish 3 [hp_x] in 1 ml - for temporary relief of skin rash, childhood illness, headache, weight loss, mental and physical fatigue, fever, cough, flu-like symptoms, heart palpitations, virus, pain, swelling, stiffness of limbs. for temporary relief of skin rash, childhood illness, headache, weight loss, mental and physical fatigue, fever, cough, flu-like symptoms, heart palpitations, virus, pain, swelling, stiffness of limbs.

ऑस्ट्रेलिया - अंग्रेज़ी - Department of Health (Therapeutic Goods Administration)

esl biosciences australia 2012 pty ltd - ct726 - japanese encephalitis virus ivds - ivds that are intended to be used in testing to provide information about infection with or exposure to japanese encephalitis virus